Blood and genomics最新文献

Significance of alanine aminotransferase testing in blood donor screening in Chongqing, China: a 7-year retrospective analysis 丙氨酸转氨酶检测在中国重庆献血者筛查中的意义:一项7年回顾性分析

Blood and genomics Pub Date : 2023-01-01 DOI: 10.46701/bg.2023022023016

Min Song, Zhenrui Xue, Yahan Fan, Ziyi Xia, Chenxi Liu, Linxiao Yan, Chunyan Yao

引用次数: 0

Long-term efficacy of haploidentical hematopoietic stem cell transplantation in the treatment of pediatric acute leukemia 单倍体造血干细胞移植治疗小儿急性白血病的长期疗效观察

Blood and genomics Pub Date : 2023-01-01 DOI: 10.46701/bg.2023022022039

Jiali Li, Ting Chen, Xixi Xiang, Peiyan Kong, Jun Rao, Xiaoqi Wang, Lei Gao, Cheng Zhang, Xi Zhang, Li Gao

{"title":"Long-term efficacy of haploidentical hematopoietic stem cell transplantation in the treatment of pediatric acute leukemia","authors":"Jiali Li, Ting Chen, Xixi Xiang, Peiyan Kong, Jun Rao, Xiaoqi Wang, Lei Gao, Cheng Zhang, Xi Zhang, Li Gao","doi":"10.46701/bg.2023022022039","DOIUrl":"https://doi.org/10.46701/bg.2023022022039","url":null,"abstract":"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the optimal treatment for pediatric patients with high-risk or intermediate-acute myeloid leukemia. Immunotherapies, such as CAR-T cellular therapy, have been rapidly developed, especially for refractory acute lymphoblastic leukemia. However, they are relatively expensive, limiting their widespread use. For patients lacking matched sibling donors, haploidentical donors are an option. This study analyzed the clinical outcomes of 119 pediatric acute leukemia patients who underwent haploidentical HSCT (n=68) or human leukocyte antigen (HLA)-matched HSCT (n=51). The 2-year overall survival (OS) and leukemia-free survival (LFS) in the haploidentical HSCT group were similar to those in the HLA-matched HSCT group (77.6% vs. 88.6%, P=0.076; 55.6% vs. 52.9%, P=0.497). The 3-year probability of total chronic graft-versus-host disease (GVHD) was 21.4% and 34.1% in the haploidentical and HLA-matched HSCT groups, respectively (P=0.526). Analysis of the 3-year cumulative recurrence rate suggested no significant difference between the haploidentical HSCT group and HLA-matched HSCT group (cumulative incidence, 32.7% vs. 31.2%, P=0.801). The cumulative incidence of acute GVHD, non-relapse mortality (NRM), and graft-versus-host relapse-free survival (GRFS) were similar in both groups. There was no difference in transplantation-related toxicity (TRT) in terms of infection, hepatic dysfunction, oral mucositis, and engraftment syndrome between the haploidentical HSCT and HLA-matched HSCT groups. The study suggests that haploidentical HSCT shows comparable OS, LFS, and GRFS to HLA-matched HSCT in pediatric patients with acceptable complications, and can therefore be recommended as an effective alternative for this population.","PeriodicalId":87226,"journal":{"name":"Blood and genomics","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135758594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of E-COD regimen in the treatment of HHV-8 negative multicentric Castleman disease E-COD方案治疗HHV-8阴性多中心Castleman病的疗效观察

Blood and genomics Pub Date : 2023-01-01 DOI: 10.46701/bg.2023022022037

Xiaoyu Liu, Huihan Wang

{"title":"Efficacy of E-COD regimen in the treatment of HHV-8 negative multicentric Castleman disease","authors":"Xiaoyu Liu, Huihan Wang","doi":"10.46701/bg.2023022022037","DOIUrl":"https://doi.org/10.46701/bg.2023022022037","url":null,"abstract":"Castleman disease (CD) is a rare and heterogeneous disease whose treatment options and prognosis vary with clinical types. Multicentric Castleman disease (MCD) is characterized by poor prognosis, and effective treatment options are still being explored. This study aimed to determine whether the E-COD (E: etoposide 50 mg/m2/d, d1–3; C: phosphoramide 750 mg/m2, d1, d3; O: vincristine 2 mg, d1; D: dexamethasone 10 mg/d, d1–5) regimen is effective in treating human herpesvirus-8 (HHV-8)-negative MCD. A group of patients diagnosed with MCD at Shengjing Hospital of China Medical University were treated with E-COD regimen. The effectiveness evaluation was conducted after four treatment cycles and follow-up for survival. A total of 101 patients were included in this study from January 2003 to December 2021, of whom 29 patients had HHV-8 negative MCD subtype. Seven HHV-8 negative MCD patients received four courses of E-COD chemotherapy. The complete response, partial response, and stable disease were 14.3%, 71.4%, and 14.3%, respectively. The follow-up ended on June 1, 2021. Two patients died, and five patients survived, with a survival period ranging from 2 to 11 years. This study suggests that the E-COD regimen is a safe, efficient, and affordable therapy option for HHV-8 negative MCD patients.","PeriodicalId":87226,"journal":{"name":"Blood and genomics","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135758595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Guideline for the collection and preparation of non-transfusion autologous platelet concentrate or platelet-rich plasma from patients in hospitals 医院患者非输血自体浓缩血小板或富血小板血浆采集和制备指南

Blood and genomics Pub Date : 2021-01-01 DOI: 10.46701/bg.2021022021128

Jianjun Wu, Guiqiu Shan, Maohong Bian, Xin Cui, G. Ding, Yahan Fan, Jianping Li, Zhongjun Li, Jiubo Liu, Hua Lu, Qun Luo, Shijie Mu, Mei Qin, Haiyan Wang, Jiang Wu, D. Xia, Rong Xia, Pu Xu, Guihua Yang, Wen-zhen Yin, Zebo Yu, Juan Zhang, Lili Zhu, Peiyuan Zhu, J. Gong, Shu-ming Zhao

引用次数: 0

Comment on "An enzymatic pathway in the human gut microbiome that converts A to universal O type blood"[1] 评论“人类肠道微生物群中将A型血转化为通用O型血的酶途径”[1]

Blood and genomics Pub Date : 2021-01-01 DOI: 10.46701/bg.2021022021122

Xueying Wang, Zhongjun Li

引用次数: 0

Treatment of stage IIIB squamous-cell lung cancer with pembrolizumab combined with chemotherapy to achieve pCR: a case report 派姆单抗联合化疗实现pCR治疗IIIB期鳞状细胞肺癌1例报告

Blood and genomics Pub Date : 2021-01-01 DOI: 10.46701/bg.2021022021121

Fanghao Liu, Hao-yu Li, Yunfeng Miao, Guoli Lv

引用次数: 0

Evidence for AJUBA-catenin-CDH4-linked differentiation resistance of mesenchymal stem cells implies tumorigenesis and progression of head and neck squamous cell carcinoma: a single-cell transcriptome approach. ajuba -catenin- cdh4相关间充质干细胞分化抵抗的证据表明头颈部鳞状细胞癌的肿瘤发生和进展:单细胞转录组方法。

Blood and genomics Pub Date : 2021-01-01 DOI: 10.46701/BG.2021012021106

Andres Stucky, Li Gao, Lan Sun, Shengwen Calvin Li, Xuelian Chen, Tiffany H Park, Jin Cai, Mustafa H Kabeer, Xi Zhang, Uttam K Sinha, Jiang F Zhong

{"title":"Evidence for AJUBA-catenin-CDH4-linked differentiation resistance of mesenchymal stem cells implies tumorigenesis and progression of head and neck squamous cell carcinoma: a single-cell transcriptome approach.","authors":"Andres Stucky, Li Gao, Lan Sun, Shengwen Calvin Li, Xuelian Chen, Tiffany H Park, Jin Cai, Mustafa H Kabeer, Xi Zhang, Uttam K Sinha, Jiang F Zhong","doi":"10.46701/BG.2021012021106","DOIUrl":"10.46701/BG.2021012021106","url":null,"abstract":"An increasing number of reports indicate that mesenchymal stem cells (MSCs) play an essential role in promoting tumorigenesis and progression of head and neck squamous cell carcinoma (HNSCC). However, the molecular mechanisms underlying this process remain unclear. Using the MSC model system, this study analyzes the molecular pathway by which differentiation resistant MSCs promote HNSCC. MSCs were cultured in osteogenic differentiation media and harvested on days 12 and 19. Cells were stained for cell differentiation analysis using Alizarin Red. The osteogenesis-resistant MSCs (OR-MSCs) and MSC-differentiation-derived osteoblasts (D-OSTBs) were identified and subjected to the single-cell transcriptome analysis. Gene-specific analyses of these two sub-populations were performed for the patterns of differential expression. A total of 1 780 differentially expressed genes were determined to distinguish OR-MSCs significantly from D-OSTB. Notably, AJUBA, β-catenin, and CDH4 expression levels were upregulated considerably within the OR-MSCs compared to D-OSTBs. To confirm their clinical relevance, a survey of a clinical cohort revealed a high correlation among the expression levels of AJUBA, β-catenin and CDH4. The results shed new light that OR-MSCs participate in the development of HNSCC via a pathway mediated by AJUBA, β-catenin, CDH4, and CTNNB1, thereby implying that MSC-based therapy is a promising therapeutic approach in the management of HNSCC.","PeriodicalId":87226,"journal":{"name":"Blood and genomics","volume":"5 1","pages":"29-39"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346230/pdf/nihms-1725724.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39293020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasma microRNA profiling highlights miR-1260b and miR-720 as novel diagnostic and prognostic biomarkers of esophageal squamous cell carcinoma 血浆microRNA分析强调miR-1260b和miR-720是食管鳞状细胞癌新的诊断和预后生物标志物

Blood and genomics Pub Date : 2021-01-01 DOI: 10.46701/bg.2021022021115

Fuhua Wang, Yunfeng Yang, Xiangyun Guo, Feng Li, R. Yang, Xiaoyu Li, Sutang Guo, Chunya Wang

引用次数: 0

TCEP-HCl can resolve the daratumumab interference TCEP-HCl可消除达拉单抗干扰

Blood and genomics Pub Date : 2021-01-01 DOI: 10.46701/bg.2021022021124

Jingya Zhao, Zhixin Liu, Dandan Yin, Shijie Mu

引用次数: 0

Epiregulin promotes growth and metastasis of gastric cancer via the ERK/JNK/p38 signaling pathway 表调节蛋白通过ERK/JNK/p38信号通路促进胃癌的生长和转移

Blood and genomics Pub Date : 2021-01-01 DOI: 10.46701/bg.2021022021125

Qiuyan Xia, Jiajia Jiang, Wei Zhao, Q. Tang, Xiaohua Li, Tengqi Wang, Yan Zhou

引用次数: 0